3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Cisplatin
33
Radiotherapy
23
Cetuximab
18
Paclitaxel
14
Docetaxel
14
pembrolizumab
13
Carboplatin
12
Fluorouracil
10
Radiotherapy, Intensity-Modulated
8
Nivolumab
8
Drug Therapy
7
Erlotinib Hydrochloride
6
Panitumumab
5
dacomitinib
4
Radiation
4
Methotrexate
4
Esophagectomy
4
130-nm albumin-bound paclitaxel
4
durvalumab
3
ON 01910
3
Leucovorin
3
Gemcitabine
3
Chemoradiotherapy
3
vandetanib
2
palbociclib
2
osimertinib
2
nedaplatin
2
fludarabine
2
cabazitaxel
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Squamous Cell
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled